A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab

Acta Ophthalmol. 2015 Sep;93(6):e519-20. doi: 10.1111/aos.12677. Epub 2015 Apr 1.

Authors

Pierluigi Iacono¹, Maurizio Battaglia Parodi², Alexandros Papayannis³, Carlo La Spina², Monica Varano¹, Francesco Bandello²

Affiliations

¹ G. B. Bietti Foundation for study and research in ophthalmology, IRCCS, Rome, Italy.
² Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
³ Department of Ophthalmology, Hospital Conegliano Veneto, Conegliano Veneto, Italy.

PMID: 25828793
DOI: 10.1111/aos.12677

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Algorithms*
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / therapeutic use*
Choroidal Neovascularization / diagnosis
Choroidal Neovascularization / drug therapy*
Choroidal Neovascularization / physiopathology
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Male
Middle Aged
Myopia, Degenerative / diagnosis
Myopia, Degenerative / drug therapy*
Myopia, Degenerative / physiopathology
Prospective Studies
Ranibizumab / administration & dosage
Ranibizumab / therapeutic use*
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology

Substances

Angiogenesis Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A
Ranibizumab